Home » USA Broker Ratings » DexCom – Consenus Indicates Potential 21.4% Upside

DexCom – Consenus Indicates Potential 21.4% Upside

DexCom found using ticker (DXCM) now have 15 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 316 and 270 with the average target price sitting at 296.27. Given that the stocks previous close was at 244.02 this indicates there is a potential upside of 21.4%. There is a 50 day moving average of 263.68 and the 200 day MA is 207.67. The company has a market capitalisation of $19,474m. Find out more information at: http://www.dexcom.com

DexCom, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom was founded in 1999 and is headquartered in San Diego, California.

Join us on our new LinkedIn page

Follow us on LinkedIn